2014 Cancer Center Administrators Forum
description
Transcript of 2014 Cancer Center Administrators Forum
Scott M. Lippman, MDDirector, Moores Cancer Center
April 14, 2014
2014 Cancer Center Administrators Forum
San Diego NCI Cancer Centers Council (C3): A Model for Multi‐Institutional Transdisciplinary Collaboration
Evolution of the Moores Cancer Center
Moores Cancer Center Opened
Cancer Center FoundedJohn Mendelsohn, Director
CCSG Renewed
Scott Lippman Director
Awarded Comprehensive
Status
NCI-designated Cancer Center
UCSD SOMFounded
Napoleone FerraraBasic Science
Razelle KurzrockClinical Science
Ezra CohenTranslational
Science
CTSA Awarded
2
CCSG Renewal
‘14
Dennis Carson Director
S t r a te g i c Re c r u i t s
UCSD Moores Cancer Center
Shared Resources
Nicholas Webster, PhD
Deputy DirectorBarbara Parker, MD
AdministrationIra Goodman, MPA, MS
Clinical Trials Office
External Advisory Board
Research Programs•Cancer Prevention•Reducing Cancer Disparities
Research Programs•Hematologic Malignancies•Solid Tumor Therapeutics
Division of Clinical Science
Razelle Kurzrock, MD
Division of Basic Science
Napoleone Ferrara, MD
Senior Advisor to the DirectorThomas Kipps, MD, PhD
Research Programs•Cancer Biology & Signaling•Cancer Genomics & Networks
Office of Industry Relations
Executive Committee
Cancer Cabinet
Board of Visitors
Division of Population Science
John Pierce, PhD
Center DirectorAssociate Vice Chancellor
for Cancer Research and CareScott Lippman, MD
Shared Resources (7)Biorepository & Tissue
TechnologyBiostatistics
Genomics & BioinformaticsMicroscopy
Flow CytometryTransgenic/KO Mice
Diet & Physical Activity
Shared Resources
Nicholas Webster, PhD
Division of Clinical Science
Razelle Kurzrock, MD
Division of Basic Science
Napoleone Ferrara, MD
Division of Population Science
John Pierce, PhD
3
Moores and Other Cancer Center Facilities on the UC San Diego Campus
MCC Moores Cancer Center
OP Outpatient Pavilion
CNT Center for Novel Therapeutics
Cancer CampusRelation to Consortium Partner SDSU
Altman CTRI CALM
JMCHCC
OP
MCC
CNT
FACILITIES
CALM Center for Advanced Laboratory Medicine
JMC Jacobs Medical Center- Hospital for Cancer Care
CTRI Clinical and Translational Research Institute
4
SCRM Sanford Consortium for Regenerative Medicine
LICR Ludwig Institute for Cancer Research
SIO Scripps Institution of Oceanography
LICR
SCRM
SIO
Catchment Area
121 miles
AZ Cancer Center410 miles
San Diego• 8th Largest city (1.33M)• 5th Largest county (3.14M)
Imperial County• Population = 175K• Poverty Rate = 23%
REGIONAL IMPACT
UC Irvine
UCLA
USC City of Hope
MCC
5
Clinical Hub of Unique Biomedical Environment
UCSD MOORES
THE SCRIPPS RESEARCH INSTITUTE
LA JOLLA ALLERGY AND IMMUNOLOGY
JCVI
2nd largest life-sciences cluster in US (Jones Lang LaSalle)
• Advisory & Innovation Council• Center for Novel Therapeutics (CNT)
LIFE TECHNOLOGIES
AMGEN
JANSSEN
NOVARTIS
ILLUMINA
PFIZER
MERCK
6
SDSU
16 milesJCVI
Sanford Consortium for Regenerative Medicine(opened Dec 2011; LIAI, Salk, S-B, MCC, TSRI)
SDSU San Diego State University(Formal consortium MOU signed Apr 2013)
(C3 MOU signed Oct 2012)
J. Craig Venter Institute - HLI(opened Nov 2013; HLI MOU signed Feb 2014)
SALK
SANFORD | BURNHAM
SCRM SALK
SANFORD | BURNHAM
C3 MOU signed(Oct 12, 2012)
MCC / C3 Formal Affiliations / Timeline
SDSU: Federally-designated Hispanic-serving Institute
(April 2012)
C3 Retreat(June 29,
2013)
Members from TSRI, LIAI & JCVI join MCC facultySanford Consortium for
Regenerative Medicine (SCRM) opens (Dec 2011)
C3 Pilot Grant RFA(Feb 28, 2014)
Pedal the Cause Fundraiser
(Oct 26, 2013)
HLI MOU signed (Feb 2014)
SDSU: Formal consortium w/ MCC
MOU signed (Apr 2013)
Mahajani Symposium (Sep 9, 2013)
JCVI opened on UCSD Campus (Nov 2013)
C3 Reception at AACR
(Apr 7, 2014)
C3 Pilot Grant Awards
(May 1, 2014)
2012 2013 2014
Salk Gene Transfer Targeting S-B High Throughput ScreeningMCC Biorepository
C3 Steering Committee
Chair (rotating)
Scott M. Lippman (UCSD Moores) *
Co-Chairs
Tony Hunter (Salk)Garth Powis (Sanford-Burnham)
* All three Institutes are represented on the AACR Board of Directors in 2014
Members
Webster Cavenee (UCSD Moores)David Cheresh (UCSD Moores)Barbara Parker (UCSD Moores)
Ron Evans (Salk) *Inder Verma (Salk)Geoff Wahl (Salk)
Sara Courtneidge (Sanford-Burnham)Ze’ev Ronai (Sanford-Burnham)Kristiina Vuori (Sanford-Burnham) *
Ira Goodman (UCSD Moores)A.D. Admin
Participating SRs:• Negotiated an agreement to share unique resources at each institution that are
unavailable at the other 2 Cancer Centers (CC)
• All institutions agreed to give CC members, no matter the institution, the same priority and rates as internal CC users
• Institutions agreed to reduce the IDC charged to users from the other 2 CC Moores: from 45% to 16% (SOM Dean agreed to waive 29% academic
portion)Salk: from 95% to 16%SBMRI: from 35% to 16%
• CC agreed to cover IDC (16%) using developmental funds from their respective CCSGs (not part of formal agreement)
• All institutions agreed that standard services provided by the shared resources would not involve intellectual property
• C3 agreement has increased usage of the three cores by users at the other CCs during the first year
C3 Resource Sharing
CANCER CENTERS COUNCIL
Sanford | Burnham Cancer Center – High Throughput Screening CoreShared Resources Director
Craig Hauser, PhDCore Leader
Michael Jackson, PhDCore Users
Matthew Petroski, PhDJeffrey Smith, PhD Robert Wechsler-Reya, PhD
Salk Cancer Center – Gene Transfer Targeting and Therapeutics Core Shared Resources Director
James Fitzpatrick, PhDCore Leader
Leszek Lisowski, PhDCore Users
Jan Karlseder, PhDBen Spike, PhD
UC San Diego Moores Cancer Center – Biorepository CoreShared Resources Director
Nicholas Webster, PhDCore Leader
Scott VandenBerg, MD, PhDCore Users
Clark Chen, MD, PhDFrank Furnari, PhDMichael Karin, PhDAndrew Lowy, MD
C3 Scientific Retreat:June 29, 2013
Keynote Address
Tony Hunter, PhD“Tyrosine Kinases in Cancer Biology and Treatment: Past, Present, Future”
Support for C3 Team Science
C3 Website & Pilot Grant RFA
www.sdcancercouncil.org
C3 Pilot Grant Applications
PI Title InstitutionsBall/Kang Predictive microenvironment for testing leukemia therapies Moores/SBMRI
Castro/Burkhart Targeting the Spliceosome in CLL Moores/Moores
Chen/Snyder Harnessing the anti-glioblastoma activity of extracellular vesicles (EV) derived from human neural stem cells (hNSCs) Moores/SBMRI
Durden/Snyder Effects of dual PI-3K/Brd4 bromodomain inhibitors on NSCs and transformed NSCs Moores/SBMRI
Field/Jackson Small molecule screen for inhibitors of the GOLPH3 pathway Moores/SBMRI
Harismendy/Wechsler-Reya Mechanisms of resistance to HDAC inhibitors in medulloblastoma Moores/SBMRI
Husain/Shaw Oncogene addicted metabolic reprogramming of circulating tumor cells in lung adenocarcinoma Moores/Salk
Karin/Wahl Applying p38 MAPK inhibitors to tackle breast cancer metastasis Moores/Salk
Li/Zhou Circulating microRNA in lung cancer early diagnosis Moores/SBMRI
Lowy/Wahl Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy Moores/Salk
Madlensky/Wahl Demonstrating the clinical utility of whole exome sequencing for cancer patients Moores/Salk
Niwa/Heynan-Genel Dissecting two distinct IRE1 RNase activities as a new therapeutic strategy in multiple myeloma and other cancers Moores/SBMRI
Puri/Schwab Abl-mediated tyrosine-phosphorylation of p300 acetyl-transferase as a biomarker for tumor chemo-resistance and dasatinib-sensitivity Moores/SBMRI
Rana/Ramamoorthy Identification of non-coding RNA targets in oncogenic KRAS driven colon cancer SBMRI/Moores
Sicklick/Wechsler-Reya Targeting imatinib-resistant, KIT-negative cells in human GISTs Moores/SBMRI
Strongin/Bouvet PTK7 pseudokinase, a novel marker and a drug target in metastatic cancer SBMRI/Moores
Yu/Rana APOBEC deaminases in primary and metastatic melanoma Moores/SBMRI
Field/Jackson Small molecule screen for inhibitors of the GOLPH3 pathway Moores/SBMRI
Lowy/Wahl Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy Moores/Salk
new
Scott M. Lippman, MDDirector, Moores Cancer Center
Chugai Pharmaceutical Chair, Professor of MedicineAssociate Vice Chancellor for Cancer Research and Care
San Diego NCI Cancer Centers Council (C3): A Model for Multi‐Institutional Transdisciplinary Collaboration